- Trials with a EudraCT protocol (206)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
206 result(s) found for: Bacterial Infections AND Pneumonia, Bacterial.
Displaying page 3 of 11.
EudraCT Number: 2011-004650-25 | Sponsor Protocol Number: 110521 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, open, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-dose pr... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants against Streptococcus pneumonia, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and polio diseases) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002727-15 | Sponsor Protocol Number: 114174 | Start Date*: 2015-06-22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000826-23 | Sponsor Protocol Number: 113199 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for booster immunization of healthy children previously primed with 3 doses of pneumococcal conjugate vaccine [Pn-Pn group] or a two-dose catch-up immunization in unprimed child... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000162-38 | Sponsor Protocol Number: 113151 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III open-label study to assess the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ Infanr... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for three-dose primary vaccination against Streptococcus pneumoniae in healthy infants between 6 to 12 weeks of age at the time of the first vaccination) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003711-39 | Sponsor Protocol Number: 113166 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for booster immunization of healthy children previously primed with 3 doses of pneumococcal conjugate vaccine or a two-dose catch-up immunization in unprimed children in the sec... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000819-82 | Sponsor Protocol Number: 113266 | Start Date*: 2015-05-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, multi-centre, open study to assess antibody persistence after completion of the 3-dose primary vaccination course with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjuga... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (a single-dose booster vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases in healthy children ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001506-34 | Sponsor Protocol Number: 112933 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, controlled, single-blind study to assess the reactogenicity, safety and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine ... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Booster vaccination at 12-18 months of age against Streptococcus pneumoniae and Haemophilus influenzae type b in healthy children primed with the same study vaccines in study 10... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001511-12 | Sponsor Protocol Number: 109861 | Start Date*: 2015-06-10 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine in Taiwan when co-admini... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b diseases and a two dose primar... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001505-14 | Sponsor Protocol Number: 110808 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, controlled, single-blind study to evaluate the non-inferiority of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine compared to the 7-valent pneumococca... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae and Haemophilus influenzae t... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000101-12 | Sponsor Protocol Number: 111654 | Start Date*: 2015-05-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, multi-centre, double-blind, randomised study to assess the non-inferiority of a commercial lot of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vacc... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three-dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases, either a two-dose or t... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004644-22 | Sponsor Protocol Number: 111188 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, single-blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 10 weeks of age at the time of the first vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertus... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000557-21 | Sponsor Protocol Number: 107007 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compar... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003479-36 | Sponsor Protocol Number: 115992 | Start Date*: 2015-05-20 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, controlled, partially-blind study to assess the reactogenicity, safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influen... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Two-dose primary vaccination of healthy infants 6-12 weeks of age at the time of first vaccination against S. pneumoniae and H. influenzae according to a 2 months interval sched... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003710-16 | Sponsor Protocol Number: 112640 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, open, controlled study in healthy Japanese children to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for active immunization against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 2 years of age) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005268-29 | Sponsor Protocol Number: REIPI-RIF-IMP | Start Date*: 2008-02-13 | |||||||||||||||||||||
Sponsor Name:University Hospital Virgen del Rocío, Andalousian Health Service | |||||||||||||||||||||||
Full Title: Eficacia y seguridad del tratamiento de infecciones nosocomiales graves causadas por Acinetobacter baumannii multirresistente con rifampicina más imipenem. Efficacy and safety to the treatment of s... | |||||||||||||||||||||||
Medical condition: Neumonía, bacteriemia e infección complicada de piel y partes blandas causadas por Acinetobacter baumannii. Pneumonia, bacteremia and complicated skin and soft-tissue infections caused by Acinetoba... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005743-27 | Sponsor Protocol Number: 116485,SPNG-009 | Start Date*: 2012-05-02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccines (2830929A and 2830930A) adminis... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: 3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 1... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005187-25 | Sponsor Protocol Number: BUC-SI-11-001 | Start Date*: 2012-05-31 | |||||||||||
Sponsor Name:SOCIETA' LABORATORIO FARMACEUTICO S.I.T. SRL | |||||||||||||
Full Title: Efficacy and tolerability clinical trial of an immunostimulant made from inactivated bacteria (BUCCALIN) in the prophylaxis of infection of the airways (rhinotracheobronchitis, colds). Double-blind... | |||||||||||||
Medical condition: Episodes classified by upper respiratory infections (otitis, tonsillitis, sinusitis, pharyngotonsillitis, nasopharyngitis) and lower respiratory tract (bronchitis, pneumonia). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001406-15 | Sponsor Protocol Number: NACATB | Start Date*: 2018-07-19 | |||||||||||
Sponsor Name:Fundació Clínic per la Recerca Biomèdica | |||||||||||||
Full Title: Adequate duration of antibiotic treatment in community acquired pneumonia categorized by pneumonia severity index (PSI) | |||||||||||||
Medical condition: Community Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001654-21 | Sponsor Protocol Number: KKS-279 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Justus-Liebig-University Gießen | |||||||||||||
Full Title: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia | |||||||||||||
Medical condition: COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005138-38 | Sponsor Protocol Number: 2602-415 | Start Date*: 2005-02-07 |
Sponsor Name:Hvidovre Hospital | ||
Full Title: Antibiotikaprofylakse ved vaginalplastik | ||
Medical condition: Uterine prolapse grade I-II, cystocele and/or rectocele and/or enterocele grade I - IV and/or defects of the perineal body where there is medical indication for vaginal repair, but no indication fo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
